|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | Audited | Net Sales | 4.02 | 4.29 | 17.13 | 15.33 | Total Expenditure | 3.45 | 13.77 | 23.76 | 3.28 | PBIDT (Excl OI) | 0.57 | -9.48 | -6.63 | 12.05 | Other Income | 0 | 0 | 6.59 | 0 | Operating Profit | 0.57 | -9.48 | -0.04 | 12.05 | Interest | 0 | 0.10 | 2.57 | 1.48 | Exceptional Items | 0 | 0 | 0 | 0 | PBDT | 0.57 | -9.58 | -2.61 | 10.57 | Depreciation | 0.20 | 0.20 | 0.20 | 0.30 | Profit Before Tax | 0.37 | -9.78 | -2.81 | 10.27 | Tax | 0 | -1.07 | 0 | 7.65 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 0.37 | -8.71 | -2.81 | 2.62 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 0.37 | -8.71 | -2.81 | 2.62 | Equity Capital | 494.22 | 494.22 | 494.22 | 123.36 | Face Value (IN RS) | 2 | 2 | 2 | 2 | Reserves | | | | | Calculated EPS | 0.00 | -0.04 | -0.01 | 0.04 | Calculated EPS (Annualised) | 0.01 | -0.14 | -0.05 | 0.17 | No of Public Share Holdings | 247,111,478.00 | 247,111,478.00 | 247,111,478.00 | 61,678,960.00 | % of Public Share Holdings | 100.00 | 100.00 | 100.00 | 100.00 | | | | | | PBIDTM% (Excl OI) | 14.18 | -220.98 | -38.70 | 78.60 | PBIDTM% | 14.18 | -220.98 | -0.23 | 78.60 | PBDTM% | 14.18 | -223.31 | -15.24 | 68.95 | PBTM% | 9.20 | -227.97 | -16.40 | 66.99 | PATM% | 9.20 | -203.03 | -16.40 | 17.09 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|